Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic breast cancerBria-OTS™ to be studied as monotherapy and in combination...
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical modelsNovel therapy activates...
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations...
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patientsMultiple...
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)Primary endpoint is overall survival (OS) with...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with “Eye-Bulging” metastatic breast cancerHeavily pre-treated patient had failed 8...
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMT™ to...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.17 | 20.2380952381 | 0.84 | 1.12 | 0.78 | 38816 | 0.92773727 | CS |
4 | -0.24 | -19.2 | 1.25 | 1.27 | 0.78 | 23422 | 0.96994992 | CS |
12 | -0.04 | -3.80952380952 | 1.05 | 2.53 | 0.64 | 61083 | 1.06481124 | CS |
26 | -1.06 | -51.2077294686 | 2.07 | 2.53 | 0.64 | 33472 | 1.11088014 | CS |
52 | -5.14 | -83.5772357724 | 6.15 | 8 | 0.64 | 20670 | 1.67283647 | CS |
156 | -9.83 | -90.6826568266 | 10.84 | 15.05 | 0.64 | 11964 | 4.61340319 | CS |
260 | -9.83 | -90.6826568266 | 10.84 | 15.05 | 0.64 | 11964 | 4.61340319 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관